ANANDKUMAR PANCHAL: Open Payments
NPI 1629453303 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,229 in 23 payments from 8 companies in 2025. Trend: 2023 $1,069 · 2024 $2,225 · 2025 $2,229
Food & beverage: $2,229
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $504 |
| Teva Pharmaceuticals USA, Inc. | 3 | $373 |
| Janssen Pharmaceuticals, Inc | 3 | $285 |
| Otsuka America Pharmaceutical, Inc. | 2 | $238 |
| Alkermes, Inc. | 3 | $222 |
| Axsome Therapeutics, Inc. | 2 | $220 |
| ABBVIE INC. | 2 | $212 |
| Neurocrine BioSciences, Inc. | 4 | $176 |
Products named: CAPLYTA, INVEGA SUSTENNA, AUSTEDO XR, Auvelity, VRAYLAR, INGREZZA, UZEDY, ABILIFY MAINTENA.
Industry payments across TX — which companies pay providers there.
